It is difficult to predict when Wegovy will be approved in Quebec. The timing will depend on the company's interest in entering the Canadian market and submitting an application to Health Canada for approval. Currently, there has been no application made to Health Canada for Wegovy. The medication is already authorized in the United States this year. Typically, medications are approved by the FDA in the US a few years before Health Canada approves them. The process of reviewing a new medication application by Health Canada can take 6 to 12 months. However, since Wegovy's active ingredient, semaglutide, is already available in Canada under the name Ozempic for diabetes treatment, this may expedite the approval process. Wegovy's main difference is that it allows for a higher dosage for weight loss compared to Ozempic. It is expected that Wegovy may not be on the market in Quebec for at least the next two years.